{
"id":"mk19_bb_hm_s9",
"subspecialtyId":"hm",
"title":"Plasma Cell Dyscrasias",
"jsonContent":{
"type":"section",
"id":"mk19_bb_hm_s9",
"title":{
"__html":"Plasma Cell Dyscrasias"
},
"titleNode":{
"type":"section-title",
"hlId":"4c7b74",
"children":[
"Plasma Cell Dyscrasias"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_hm_s9_0",
"children":[
{
"type":"p",
"hlId":"c6a0bc",
"children":[
"Plasma cell dyscrasias consist of abnormal clonal proliferation of immune globulin–secreting differentiated B lymphocytes and plasma cells. ",
{
"type":"alert",
"children":[
"Multiple myeloma is the most common malignant plasma cell dyscrasia."
]
},
" Other common plasma cell dyscrasias include ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"monoclonal gammopathy of undetermined significance",
"children":[
"MGUS"
]
},
","
]
},
" Waldenström macroglobulinemia, and light-chain–associated amyloidosis (",
{
"type":"abbreviation",
"title":"amyloidosis immunoglobulin light-chain amyloidosis",
"children":[
"AL"
]
},
" amyloidosis). MGUS and multiple myeloma are characterized by a serum monoclonal protein. Patients with MGUS should be periodically reassessed after initial diagnosis for development of multiple myeloma or AL amyloidosis."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s9_1",
"title":{
"__html":"Multiple Myeloma"
},
"titleNode":{
"type":"section-title",
"hlId":"b494bb",
"children":[
"Multiple Myeloma"
]
},
"children":[
{
"type":"p",
"hlId":"d7b53e",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Diagnosis:"
]
},
" The CRAB mnemonic encompasses most myeloma-related signs and symptoms:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"2f4632",
"children":[
"C (hyper",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"C"
]
},
"alcemia)"
]
},
" ",
{
"type":"list-item",
"hlId":"5d6c5c",
"children":[
"R (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"R"
]
},
"enal failure)"
]
},
" ",
{
"type":"list-item",
"hlId":"e5acd2",
"children":[
"A (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"A"
]
},
"nemia)"
]
},
" ",
{
"type":"list-item",
"hlId":"e1f38c",
"children":[
"B (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"B"
]
},
"one disease: lytic lesions, fractures, or osteoporosis)"
]
},
" "
]
},
{
"type":"p",
"hlId":"8d8a23",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Testing:"
]
},
" Diagnostic tests for multiple myeloma include ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"complete blood count",
"children":[
"CBC"
]
},
";"
]
},
" serum chemistries; ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"serum protein electrophoresis",
"children":[
"SPEP"
]
},
";"
]
},
" 24-hour ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"urine protein electrophoresis",
"children":[
"UPEP"
]
},
";"
]
},
" serum and urine immunofixation assays; serum free light chain testing; and serum IgG, IgA, and IgM measurements. Think of multiple myeloma in patients with a low anion gap."
]
},
{
"type":"p",
"hlId":"d8f0d8",
"children":[
"Whole body, low-dose CT or ",
{
"type":"abbreviation",
"title":"positron emission tomography",
"children":[
"PET"
]
},
"-CT is recommended to detect lytic bone lesions."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_bb_hm_s9_inline_t1"
],
"forceOpen":true
},
{
"type":"p",
"hlId":"83eb62",
"children":[
"Most smoldering multiple myeloma progresses to multiple myeloma requiring therapy or to AL amyloidosis."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"6b510d",
"children":[
"In patients with myeloma and back pain, MRI should also be performed to assess for spinal cord impingement, even in the absence of motor or sensory deficits."
]
},
" ",
{
"type":"list-item",
"hlId":"c527a7",
"children":[
"Do not use bone scans in patients with suspected myeloma because they are not as sensitive as a CT or PET-CT."
]
},
" "
]
},
{
"type":"p",
"hlId":"533056",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Treatment:"
]
},
" Treat multiple myeloma requiring therapy with induction chemotherapy."
]
},
{
"type":"p",
"hlId":"dd3be1",
"children":[
"Following induction chemotherapy, autologous ",
{
"type":"abbreviation",
"title":"hematopoietic stem cell transplantation",
"children":[
"HSCT"
]
},
" may be considered."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"165d2f",
"children":[
"Do not treat MGUS."
]
},
" ",
{
"type":"list-item",
"hlId":"5dd934",
"children":[
"Bortezomib and thalidomide used in induction chemotherapy are associated with a high risk of peripheral neuropathy."
]
},
" ",
{
"type":"list-item",
"hlId":"d7fbec",
"children":[
"Thalidomide, lenalidomide, or pomalidomide used in induction chemotherapy is associated with an increased risk of ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"venous thromboembolism",
"children":[
"VTE"
]
},
"."
]
}
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s9_2",
"title":{
"__html":"AL Amyloidosis"
},
"titleNode":{
"type":"section-title",
"hlId":"72ad86",
"children":[
"AL Amyloidosis"
]
},
"children":[
{
"type":"p",
"hlId":"6ba01a",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Diagnosis:"
]
},
" AL amyloidosis is found in 10% of patients with multiple myeloma but may be diagnosed in patients who lack other myeloma findings."
]
},
{
"type":"p",
"hlId":"912d21",
"children":[
"Findings in AL amyloidosis include:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"63e126",
"children":[
"nephrotic syndrome with enlarged kidneys on ultrasound"
]
},
" ",
{
"type":"list-item",
"hlId":"12b602",
"children":[
"delayed gastric emptying, intestinal pseudo-obstruction, malabsorption"
]
},
" ",
{
"type":"list-item",
"hlId":"9600d1",
"children":[
"hepatomegaly, elevated alkaline phosphatase, and portal hypertension"
]
},
" ",
{
"type":"list-item",
"hlId":"4e818b",
"children":[
"distal sensorimotor polyneuropathy"
]
},
" ",
{
"type":"list-item",
"hlId":"c22f6c",
"children":[
"restrictive cardiomyopathy with granular appearance on echocardiography"
]
},
" ",
{
"type":"list-item",
"hlId":"6cfbb6",
"children":[
{
"type":"abbreviation",
"title":"left ventricular hypertrophy",
"children":[
"LVH"
]
},
" by echocardiography, low voltage ",
{
"type":"abbreviation",
"title":"electrocardiogram",
"children":[
"ECG"
]
}
]
},
" ",
{
"type":"list-item",
"hlId":"be267f",
"children":[
"bleeding diathesis, periorbital purpura, factor X deficiency with prolonged ",
{
"type":"abbreviation",
"title":"prothrombin time",
"children":[
"PT"
]
},
" and ",
{
"type":"abbreviation",
"title":"activated partial thromboplastin time",
"children":[
"aPTT"
]
}
]
},
" ",
{
"type":"list-item",
"hlId":"fdc78f",
"children":[
"macroglossia"
]
},
" "
]
},
{
"type":"p",
"hlId":"af1bd8",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Testing:"
]
},
" Confirmation of AL amyloidosis requires:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"e48360",
"children":[
"abdominal fat pad aspirate or bone marrow biopsy demonstrating apple green birefringence under polarized light with Congo red staining"
]
},
" ",
{
"type":"list-item",
"hlId":"8c3ca0",
"children":[
"κ/λ light-chain detection and typing"
]
},
" ",
{
"type":"list-item",
"hlId":"5bb512",
"children":[
"presence of an M protein on serum or urine testing or clonal plasma cells in the marrow"
]
},
" "
]
},
{
"type":"p",
"hlId":"2b6768",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Treatment:"
]
},
" Treatment algorithms for AL amyloidosis are similar to those for multiple myeloma."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"ede843",
"children":[
"Abdominal fat pad or bone marrow biopsy has a high yield and is safer than liver, kidney, or heart biopsy in establishing the diagnosis of AL amyloidosis."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s9_3",
"title":{
"__html":"Waldenström Macroglobulinemia"
},
"titleNode":{
"type":"section-title",
"hlId":"94adf3",
"children":[
"Waldenström Macroglobulinemia"
]
},
"children":[
{
"type":"p",
"hlId":"b53d70",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Diagnosis:"
]
},
" Waldenström macroglobulinemia is a neoplastic infiltrate consisting of:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"778257",
"children":[
"clonal lymphocytes, plasmacytoid lymphocytes, plasma cells, and immunoblasts comprising >10% of the bone marrow cellularity ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
}
]
}
]
},
" ",
{
"type":"list-item",
"hlId":"023f60",
"children":[
"M-protein level >3 g/dL ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"and"
]
}
]
}
]
},
" ",
{
"type":"list-item",
"hlId":"cfb240",
"children":[
"presence of disease-related signs, symptoms, or organ dysfunction"
]
},
" "
]
},
{
"type":"p",
"hlId":"f157f0",
"children":[
"Fatigue and B symptoms (fever, night sweats, weight loss) are present. One third of patients will have hyperviscosity symptoms, including headache, blurred vision, hearing loss, dizziness, altered mental status, and nasal and mucosal bleeding. Lymphadenopathy, hepatomegaly, and splenomegaly are found on physical examination. Funduscopic evaluation may reveal hyperviscosity-related findings (dilated retinal veins, papilledema, flame hemorrhages)."
]
},
{
"type":"p",
"hlId":"01a55a",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Treatment:"
]
},
" ",
{
"type":"alert",
"children":[
"Waldenström macroglobulinemia hyperviscosity syndrome is a medical emergency treated with plasmapheresis to rapidly reduce IgM levels and with chemotherapy to decrease new production."
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_bb_hm_s9_inline_t1":{
"id":"mk19_bb_hm_s9_inline_t1",
"number":1,
"bookId":"hm",
"title":{
"__html":"Study Table: Diagnosis of Multiple Myeloma and MGUS"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"033954",
"children":[
"Study Table: Diagnosis of Multiple Myeloma and MGUS"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e7960",
"class":"col hd l",
"children":[
"Multiple Myeloma/MGUS"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df5415",
"class":"col hd l",
"children":[
"Findings"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6dfb7a",
"class":"cell txt l",
"children":[
"MGUS"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8fd9ca",
"class":"cell txt l",
"children":[
"Serum monoclonal protein <3 g/dL or urinary M protein <500 mg/24 h"
]
},
" ",
{
"type":"p",
"hlId":"534f6b",
"class":"cell txt l",
"children":[
"Bone marrow clonal plasma cells <10%"
]
},
" ",
{
"type":"p",
"hlId":"1a5aa5",
"class":"cell txt l",
"children":[
"No CRAB"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"581880",
"class":"cell txt l",
"children":[
"Monoclonal gammopathy of renal significance"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe07c3",
"class":"cell txt l",
"children":[
"See Nephrology; Kidney Manifestations of Deposition Diseases"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25c392",
"class":"cell txt l",
"children":[
"Smoldering multiple myeloma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd529d",
"class":"cell txt l",
"children":[
"Serum monoclonal protein ≥3 g/dL or urinary free light chain M protein ≥500 mg/24 h"
]
},
" ",
{
"type":"p",
"hlId":"22b1bc",
"class":"cell txt l",
"children":[
"Bone marrow clonal plasma cells 10%-59%"
]
},
" ",
{
"type":"p",
"hlId":"1a5aa5",
"class":"cell txt l",
"children":[
"No CRAB"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d790d",
"class":"cell txt l",
"children":[
"Multiple myeloma requiring therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8cd885",
"class":"cell txt l",
"children":[
"Serum monoclonal protein present"
]
},
" ",
{
"type":"p",
"hlId":"9f0b2c",
"class":"cell txt l",
"children":[
"Bone marrow clonal plasma cells ≥10%"
]
},
" ",
{
"type":"p",
"hlId":"1da7da",
"class":"cell txt l",
"children":[
"CRAB positive"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}